The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction by 媛뺤꽍誘�
Copyright © 2019 The Korean Association of Internal Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1226-3303
eISSN 2005-6648
http://www.kjim.org
ORIGINAL ARTICLE
Korean J Intern Med 2019;34:1030-1039
https://doi.org/10.3904/kjim.2018.009
1Department of Medicine, 
Sungkyunkwan University School 
of Medicine, Seoul; 2Department 
of Internal Medicine, Seoul 
National University Hospital, Seoul; 
3Department of Internal Medicine, 
University of Ulsan College of 
Medicine, Seoul; 4Department 
of Internal Medicine, School of 
Medicine, Kyungpook National 
University, Daegu; 5Department 
of Internal Medicine, College of 
Medicine, The Catholic University 
of Korea, Seoul; 6Department 
of Internal Medicine, Yonsei 
University College of Medicine, 
Seoul; 7Department of Internal 
Medicine, Seoul National University 
Bundang Hospital, Seongnam; 
8Department of Internal Medicine, 
Yonsei University Wonju College of 
Medicine, Wonju; 9Heart Research 
Center of Chonnam National 
University, Gwangju; 10Department 
of Internal Medicine, Chungbuk 
National University College of 
Medicine, Cheongju; 11National 
Institute of Health (NIH), Osong, 
Korea
Received : January 6, 2018
Revised : March 14, 2018
Accepted : April 2, 2018
Correspondence to Jin-Oh Choi, M.D. 
Division of Cardiology, Department of Medicine, Cardiac and Vascular Center, 
Samsung Medical Center, Sungkyunkwan University School of Medicine, 81  
Irwon-ro, Gangnam-gu, Seoul 06351, Korea  
Tel: +82-2-3410-3419, Fax: +82-2-3410-3849, E-mail: choijean5@gmail.com
Background/Aims: It is unknown whether different β-blockers (BBs) have vari-
able effects on long-term survival of patients with heart failure with reduced ejec-
tion fraction (HFrEF). This study compares the effects of two BBs, carvedilol and 
bisoprolol, on survival in patients with HFrEF.
Methods: The Korean Acute Heart Failure (KorAHF) registry is a prospective 
multicenter cohort that includes 5,625 patients who were hospitalized for acute 
heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study 
population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n 
= 1,309). Among patients with BB at discharge, subgroups were formed based on 
carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity 
score matching analysis was performed.
Results: Among patients who were prescribed a BB at discharge, 60.5% received 
carvedilol and 32.7% received bisoprolol. There was a significant reduction in all-
cause mortality in those patients with HFrEF prescribed a BB at discharge com-
pared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 
95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no signifi-
cant difference in the rate of all-cause mortality between those receiving different 
types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; 
p = 0.07). Similar results were observed after propensity score matching analysis 
(508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47).
Conclusions: In the treatment of AHF with reduced EF after hospitalization, 
mortality benefits of carvedilol and bisoprolol were comparable. 
Keywords: Beta-blocker; Heart failure with reduced ejection fraction; Carvedilol; 
Bisoprolol
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INTRODUCTION
The clinical benefits of β-blockers (BBs) are well es-
tablished in patients with heart failure with reduced 
ejection fraction (HFrEF). Therefore, current guidelines 
recommend BBs in treatment of patients with stable 
HFrEF to reduce the risk of heart failure (HF) hospi-
talization and death [1,2]. Among the many types and 
classifications of BBs, three drugs (bisoprolol, sustained 
release metoprolol succinate, and carvedilol) have been 
shown to be effective in reducing the risk of death in 
patients with HFrEF [3-6]. However, most randomized 
controlled trials that have evaluated the effect of BBs 
in patients with HFrEF have compared BBs to place-
bo. Therefore, it is unknown whether the beneficial 
effects in HF are different among the well-established 
BBs. Carvedilol has β1-, β2-, and α1-receptor blocking 
effects, unlike bisoprolol and metoprolol, which are 
β1-selective receptor blockers [7]. One head-to-head 
comparison trial between carvedilol and metoprolol 
tartrate found that carvedilol increased survival in pa-
tients with chronic HF [8]. However, there are conflict-
ing results regarding clinical outcomes according to 
the use of BBs of different classes based on registry or 
meta-analysis data. In particular, there are limited data 
available to directly compare the efficacy of carvedilol 
versus bisoprolol [9-13]. 
Therefore, this study sought to compare the mor-
tality effects of carvedilol and bisoprolol prescribed at 
discharge to patients hospitalized for acute heart failure 
(AHF) using multicenter prospective registry data in 
Korea.
METHODS
Study population and data collection
Details on the study design of the Korean Acute Heart 
Failure (KorAHF) registry have been documented pre-
viously (Clinicaltrials.gov, NCT01389843) [14,15]. Briefly, 
5,625 consecutive patients from 10 tertiary hospitals in 
Korea who were hospitalized for AHF were enrolled 
between March 2011 and February 2014. Patients were 
included if they had signs or symptoms of HF such as 
lung congestion, objective findings of left ventricular 
systolic dysfunction, or structural heart disease. Demo-
graphic and clinical information, including medical 
history, signs, symptoms, laboratory results, electro-
cardiogram, echocardiography, medications, hospital 
course, and outcomes, was obtained prospectively at the 
time of admission, discharge, and during the follow-up 
period (30-day, 90-day, 180-day, 1- to 5-year annually). 
Mortality data from patients lost to follow-up were col-
lected from the National Insurance or National Death 
Records. Fig. 1 presents the distribution of the study 
population. The study protocol was approved by the In-
stitutional Review Board (IRB No. 1102-072-352) of each 
participating hospital. The written informed consent 
was waived, and from the third year of enrollment, the 
written consents were received from survivals for fur-
ther follow-up.
Definitions and outcomes
HFrEF was defined as left ventricular ejection fraction 
(LVEF) < 40% according to recent guidelines [1]. LVEF 
was assessed using the biplane Simpson technique, 
M-mode, or visual estimation [16]. Renal function was 
assessed based on the estimated glomerular filtration 
5,625 KorAHF registry 2011 March–2014 February
3,016 Patients with HFrEF who were survied at discharge
1,309 No BB at discharge
831 Carvedilol 553 Bisoprolol
1,707 BB at discharge
206 Very low dose BBa
117 Others BBb
   276 In-hospital mortality 
   176 LVEF missing
1,315 HFpEF
   842 HFmrEF
Figure 1. Study flow. KorAHF, Korean Acute Heart Failure; 
LVEF, left ventricular ejection fraction; HFpEF, heart fail-
ure with preserved ejection fraction; HFmrEF, heart failure 
with mid-range ejection fraction; HFrEF, heart failure with 
reduced ejection fraction; BB, β-blocker. aVery low dose BB 
was defined as a standardized dose of carvedilol ≤ 3.125 mg, 
bOther BBs included nebivolol, metoprolol, betaxolol, ce-
liprolol, atenolol, propranolol, amosulalol, bevantolol, and 
sotalol.
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rate according to the Modification of Diet in Renal Dis-
ease equation [17]. The primary outcome was all-cause 
death during follow-up.
Statistical analysis
Continuous variables were compared using the t test. 
Categorical variables were compared using the chi-
square test and presented as numbers and relative 
frequencies. Survival curves were assessed with Ka-
plan-Meier analyses, and the significance level was 
evaluated with the log-rank test. In order to compare 
the risk of mortality between carvedilol and bisoprolol 
groups, the Cox proportional hazard regression was 
used to calculate the hazard ratio (HR) and 95% confi-
dence interval (CI). In multivariable models, variables 
found to be either statistically significant on univariate 
analysis or clinically relevant were considered candi-
date variables. 
Propensity score matching analyses were performed 
to reduce the possibility of biased effect estimates in 
the observational studies. A full, nonparsimonious 
model was developed. All of the included variables are 
shown in Tables 1 and 2. Patients in both groups (carve-
dilol vs. bisoprolol) were matched 1:1 based on the logit 
of the propensity score with a caliper of width 0.20 of 
the standard deviation of the logit of the propensity 
score. The covariate balance achieved by matching was 
assessed by calculating the absolute standardized mean 
differences, as listed in Tables 1 and 2. The absolute 
differences of all variables between the two groups were 
Table 1. Baseline clinical and laboratory characteristics
Characteristic
Overall population Propensity matched population
Bisoprolol 
(n = 553)
Carvedilol 
(n = 831)
p value SMD
Bisoprolol 
(n = 508)
Carvedilol
 (n = 508)
p value SMD
Age, yr 65.95 ± 15.0 64.31 ± 14.5 0.43 4.3 64.94 ± 14.9 63.99 ± 14.4 0.30 6.3
Male sex 321 (58.1) 526 (63.3) 0.06 –10.8 303 (59.7) 307 (60.4) 0.85 –1.6
Current smoker 124 (22.4) 210 (25.3) 0.25 –6.7 119 (23.4) 127 (25.0) 0.61 –3.8
BMI, kg/m2 23.4 ± 3.8 23.7 ± 3.9 0.14 –8.1 23.4 ± 3.8 23.5 ± 3.7 0.63 –3.0
Hypertension 293 (53.0) 491 (59.1) 0.03a –12.3 276 (54.3) 269 (53.0) 0.71 2.8
Diabetes mellitus 217 (39.2) 318 (38.3) 0.76 2.0 201 (39.6) 196 (38.6) 0.80 2.0
Chronic kidney  
disease
67 (12.1) 116 (14.0) 0.36 –5.5 64 (12.6) 64 (12.6) > 0.99 0
Pulmonary disease 49 (8.7) 58 (7.0) 0.24 7.0 44 (8.7) 39 (7.7) 0.65 3.5
Prior HF admission 136 (24.6) 254 (30.6) 0.02a –13.4 129 (25.4) 132 (26.0) 0.89 –1.4
De novo HF 336 (60.8) 453 (54.5) 0.03a –12.7 290 (57.1) 271 (48.3) 0.26 –7.5
ICMP 205 (37.1) 342 (41.2) 0.14 –8.4 195 (38.4) 194 (38.2) > 0.99 0.4
Atrial fibrillation 115 (20.8) 182 (21.9) 0.67 –2.7 105 (20.7) 109 (21.5) 0.82 –2.0
NYHA ≥ 3 469 (84.8) 706 (85.0) > 0.99 –0.4 431 (84.8) 433 (85.2) 0.93 –1.1
SBP, mmHg 130.3 ± 26.8 133.0 ± 31.1 0.08 –9.4 130.8 ± 27.1 130.7 ± 30.0 0.98 0.2
DBP, mmHg 82.4 ± 18.7 82.3 ± 19.4 0.91 0.6 82.2 ± 18.6 82.0 ± 19.1 0.91 0.7
Pulse rate, beats/min 94.5 ± 23.5 96.6 ± 25.2 0.13 –8.5 94.8 ± 23.1 94.1 ± 25.1 0.64 3.0
LVEF, % 27.1 ± 7.1 26.3 ± 7.5 0.04a 11.3 27.1 ± 7.1 26.9 ± 7.4 0.60 3.3
Sodium, mmol/L 138.0 ± 4.3 138.0 ± 4.4 0.99 –0.1 138.0 ± 4.2 138.1 ± 4.6 0.79 –1.7
Creatinine, mg/dL 1.41 ± 1.5 1.54 ± 1.4 0.14 –8.1 1.44 ± 1.6 1.49 ± 1.5 0.58 –3.4
Hemoglobin, g/dL 12.9 ± 2.3 13.0 ± 2.2 0.55 –3.3 12.9 ± 2.3 13.0 ± 2.2 0.82 –1.4
Values are presented as mean ± SD or number (%).
SMD, standardized mean difference; BMI, body mass index; HF, heart failure; ICMP, ischemic cardiomyopathy; NYHA, New 
York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction.
aStatistically significance.
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within 10% and not statistically different (p ≥ 0.05). Cox 
proportional hazard models were used to compare the 
outcomes in the matched groups. Statistical analyses 
were performed using R Statistical Software version 
3.3.1 (R Foundation for Statistical Computing, Vienna, 
Austria). p values < 0.05 were considered statistically sig-
nificant.
RESULTS
Baseline characteristics
Overall population
Among the 3,016 patients with HFrEF who survived 
acute hospitalization, 1,707 (56.6%) received a BB upon 
discharge (Supplementary Table 1). Among those pre-
scribed a BB, 60.5% received carvedilol, while 32.7% 
received bisoprolol (Fig. 2). After excluding patients 
on very low dose BB (standardized dose of carvedilol 
≤ 3.125 mg) or other types of BB, a total of 831 patients 
on carvedilol and 553 on bisoprolol were enrolled. The 
baseline clinical and laboratory characteristics accord-
ing to group are presented in Table 1. The treatment 
strategy and outcomes of admission data are presented 
in Table 2. Compared to patients treated with bisopr-
olol, those treated with carvedilol had a higher preva-
lence of hypertension and higher incidence of previous 
HF admission history. Those in the carvedilol group 
also had a significantly lower LVEF and higher systol-
ic blood pressure at discharge than did those in the 
bisoprolol group. Aldosterone antagonists (AAs) were 
Table 2. Treatment strategy and outcomes on admission
Characteristic
Overall population Propensity matched population
Bisoprolol 
(n = 553)
Carvedilol
(n = 831)
p value SMD
Bisoprolol 
(n = 508)
Carvedilol
 (n = 508)
p value SMD
Treatments
BB dose, mg 2.50 (1.25–2.50) 6.25 (6.25–12.5) NA NA 2.50 (1.25–2.50) 6.25 (6.25–12.5) NA NA
BB dose, mg 2.3 ± 1.6 11.5 ± 8.9 NA NA 2.3 ± 1.5 11.2 ± 8.6 NA NA
BB dose equivalent, % 23.3 ± 15.9 23.0 ± 17.7 0.72 1.9 23.1 ± 15.5 22.4 ± 17.2 0.48 4.4
AAs at discharge 268 (48.5) 509 (61.3) < 0.001a –25.9 257 (50.6) 260 (51.2) 0.90 –1.2
RASB at discharge 461 (83.4) 694 (83.5) > 0.99 –0.4 423 (83.3) 427 (84.1) 0.80 –2.1
Loop diuretics 526 (95.1) 786 (94.6) 0.75 2.4 484 (95.3) 479 (94.3) 0.57 4.6
Intravenous inotropes 163 (29.5) 210 (25.3) 0.10 9.4 151 (29.7) 152 (29.9) > 0.99 –0.4
Transfusion 74 (13.4) 115 (13.8) 0.87 –1.3 69 (13.6) 72 (14.2) 0.86 –1.7
Mechanical ventilation 56 (10.1) 90 (10.8) 0.74 –2.3 53 (10.4) 55 (10.8) 0.92 –1.3
Renal replacement  
therapy
28 (5.1) 57 (6.9) 0.21 7.6 28 (5.5) 34 (6.7) 0.51 –5.3
Assist deviceb 28 (5.1) 46 (5.5) 0.79 2.1 27 (5.3) 28 (5.5) > 0.99 –0.9
Outcomes on admission
ICU admission 272 (49.2) 368 (44.3) 0.08 9.8 247 (48.6) 235 (46.3) 0.49 4.9
Length of stay, day 12.8 ± 14.1 11.6 ± 13.1 0.09 9.2 12.7 ± 14.4 12.0 ± 15.2 0.42 5.3
SBP at discharge, 
mmHg
111.3 ± 16.7 114.7 ± 17.4 < 0.001a –19.7 112.0 ± 16.9 112.3 ± 16.9 0.80 –1.6
Values are presented as median (interquartile range), mean ± SD, or number (%).
SMD, standardized mean difference; BB, β-blocker; NA, not available; AA, aldosterone antagonist; RASB, renin angiotensin 
system blocker; ICU, intensive care unit; SBP, systolic blood pressure.
aStatistically significance.
bAssist devices included intra-aortic balloon pumps, left ventricular assist devices, extracorporeal membrane oxygenation, and 
cardiac resynchronization therapy.
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more frequently prescribed to patients in the carvedilol 
group than they were to those in the bisoprolol group. 
The mean daily doses of prescribed carvedilol and bi-
soprolol were 11.2 ± 8.6 and 2.3 ± 1.6 mg, respectively. 
There was no significant difference between the two 
groups with regard to the percentage receiving the re-
spective guideline-recommended target doses (Table 2).
Propensity matched population
After performing propensity score matching, a total 
of 508 matched patient pairs from the carvedilol and 
bisoprolol groups were obtained (Tables 1 and 2). In 
the propensity matched population, there were no sig-
nificant differences between the groups with regard to 
the baseline clinical information, laboratory data, treat-
ment strategy, or outcomes from admission data with 
acceptable standardized mean differences.
Clinical outcomes
Overall population
The median follow-up duration was 28 months (inter-
quartile range, 18 to 37). There was a significantly lower 
risk of mortality in patients who were prescribed a BB 
at discharge compared to those who were not (BB vs. 
no BB, 26.1% vs. 40.8%; HR, 0.59; 95% CI, 0.52 to 0.67; p 
< 0.001) (Fig. 3). However, there was no significant dif-
ference in the rate of all-cause mortality between the 
carvedilol and bisoprolol groups (carvedilol vs. bisopro-
lol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07) 
(Table 3 and Fig. 4A). There was no significant differ-
ence in the all-cause death rate between the two groups 
after adjusting for age, sex, hypertension, diabetes 
mellitus, history of HF admission, ischemic etiology, 
systolic blood pressure at discharge, LVEF, renin angio-
tensin system blocker at discharge, or AA at discharge 
(adjusted HR, 1.22; 95% CI, 0.98 to 1.52; p = 0.07) (Table 3).
Propensity matched population
After 1:1 propensity score matching, the bisoprolol and 
carvedilol groups had a similar risk of all-cause mor-
tality (26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 
0.47) (Table 3 and Fig. 4B).
Subgroup analysis
Subgroup analysis was performed to evaluate the con-
sistency of the all-cause mortality rate between patients 
treated with carvedilol and bisoprolol in the propen-
sity-matched population (Fig. 5). The risk of all-cause 
mortality was similarly observed in various subgroups 
7%
Carvedilol
60.5%
Bisoprolol
32.7%
Nebivolol
3.0%
Othersa
3.8%
1.00
0.75
0.50
0.25
0
No BB 1,309 991 672 327
BB 1,707 1,452 1,006 457
Numbers at risk
Time (day)
Su
rv
iv
al
 p
ro
ba
bi
lit
y
365 730
Log rank p < 0.001
1,095
Figure 2. Distribution of β-blocker (BB) use at discharge. 
aOther BBs included metoprolol, betaxolol, celiprolol, aten-
olol, propranolol, amosulalol, bevantolol, and sotalol.
Figure 3. Kaplan-Meier curves for all-cause mortality in 
acute heart failure (AHF) with heart failure with reduced 
ejection fraction (HFrEF) according to β-blocker (BB) use at 
discharge. Kaplan-Meier curves for all-cause mortality of 
AHF patients with HFrEF according to the use of BB (red 
line) or no BB (blue line).
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according to patient characteristics without significant 
interaction.
β-Blocker duration and dose
Among the study population, 203 patients (14.7%) died 
or were not able to follow-up within 1 year. Among pa-
tients with HFrEF who survived more than 1 year after 
hospitalization, BB was maintained at 1-year follow-up 
in 862 patients (73.0%). There was no significant differ-
ence in proportion of maintenance of BB between the 
carvedilol and bisoprolol groups (carvedilol vs. bisopro-
lol, 71.7% [509/710] vs. 74.9% [353/771], p = 0.23). BB dose at 
1-year follow-up was increased compared to initial dose 
according to the current guidelines in both groups, and 
the follow-up dose equivalent was not significantly dif-
ferent between the two groups (Supplementary Fig. 1).
DISCUSSION
In this large contemporary cohort study in Korea, there 
was no significant difference in all-cause mortality 
Table 3. All-cause mortality of acute heart failure patients with heart failure with reduced ejection fraction according to 
β-blocker type at discharge in total population and propensity-matched population
Bisoprolol Carvedilol
Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
Overall population 553 831
All-cause death 146 (23.5) 299 (27.5) 1.21 (0.99–1.47) 0.07 1.22 (0.98–1.52) 0.07
Propensity matched population 508 508
All-cause death 121 (23.8) 133 (26.2) 1.10 (0.86–1.40) 0.47 1.19 (0.93–1.53) 0.17
Values are presented as number (%).
HR, hazard ratio; CI, confidence interval.
aAdjusted variables included age, male sex, hypertension, diabetes mellitus, history of heart failure admission, ischemic etiol-
ogy, systolic blood pressure at discharge, left ventricular ejection fraction, renin angiotensin system blocker at discharge, and 
aldosterone antagonist at discharge.
Numbers at risk Numbers at risk
Log rank p = 0.10 Log rank p = 0.47
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1.00
0.75
0.50
0.25
0
Time (day)
365 730 1,095
Bisoprolol
    Carvedilol
553
831
472
710
351
464
154
218
Bisoprolol
    Carvedilol
508
508
434
431
323
296
138
151
Figure 4. Comparison of all-cause mortality rate between treatment with carvedilol or bisoprolol. Kaplan-Meier curves for all-
cause mortality of acute heart failure patients with heart failure with reduced ejection fraction in the overall population (A) 
and propensity-matched population (B) according to use of carvedilol (red line) or bisoprolol (blue line). 
A B
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between carvedilol and bisoprolol at discharge in hos-
pitalized patients with AHF and HFrEF. The primary 
finding was consistent after performing propensity 
score matching in an effort to reduce selection bias. 
In particular, the effects of carvedilol and bisoprolol 
were consistent through various subgroups of patients. 
These subgroups included patients with ischemic eti-
ology of their HF, target dose users, those with or with-
out vasopressor requirements on admission, and those 
with atrial fibrillation and renal dysfunction. Our study 
also shows that, regardless of the type of BB used, there 
is a consistent mortality benefit in patients with AHF 
and HFrEF.
Carvedilol is a third-generation BB with competitive 
blockade of the β1-, β2-, and α1-adrenergic receptors. 
Among all BBs, carvedilol has been studied most exten-
sively in patients with HF [5,6,18-20]. Therefore, some 
investigators have suggested that, given its vasodilatory 
effect, carvedilol would have more robust clinical out-
comes in HFrEF than selective β1 inhibitors, including 
bisoprolol and metoprolol. The COMET (Carvedilol Or 
Metoprolol European Trial) study, a large randomized 
controlled trial comparing carvedilol and metoprolol, 
found that carvedilol extended survival compared to 
metoprolol in patients with chronic HF [8]. Howev-
er, this study had several critical limitations. For one, 
carvedilol was compared to short-acting metoprolol 
tartrate. However, metoprolol tartrate has not been 
Figure 5. Subgroup analysis. Comparative unadjusted hazard ratios of all-cause mortality for subgroups in the propensity 
matched population between carvedilol and bisoprolol groups. CI, confidence interval; GFR, glomerular filtration rate.
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shown to have a mortality benefit in HF and is there-
fore not recommended in the practice guidelines. In 
addition, the group used a dose of metoprolol that 
is lower than the recommended guideline doses; in 
contrast, carvedilol was prescribed at full guideline 
target dose. Another randomized trial that compared 
outcomes between different BB types was the MAIN-
CHF II study, which was a head-to-head comparison 
of bisoprolol and carvedilol in Japanese patients with 
chronic HF [21]. Unfortunately, this study was terminat-
ed early because bisoprolol was approved for use in the 
treatment of chronic HF. Given the limitations of these 
previous randomized trials, many observational studies 
and meta-analyses have been performed in an effort to 
compare different BBs in the treatment of HF. Howev-
er, the results of these studies are controversial [9-11,22].
The KorAHF registry included patients from 10 
tertiary care centers throughout Korea, and enrolled 
a relatively large number of HF patients. Fortunate-
ly, this registry provided a large number of clinical 
and laboratory variables, as well as many well-known 
prognostic factors. Consequently, we were able to per-
form propensity-matching analysis to adjust for these 
prognostic factors. The difference in mortality benefit 
between carvedilol and bisoprolol was not significant 
prior to matching and became even more negligible 
in the matched cohort. Our results and those of previ-
ous studies suggest that carvedilol and bisoprolol have 
comparable mortality benefits in patients with HFrEF. 
The current study also showed that baseline charac-
teristics of the study population according to use of 
carvedilol or bisoprolol were slightly different. Patients 
prescribed carvedilol had a higher proportion of hyper-
tension, pervious history of HF admission, and lower 
EF compared to those with bisoprolol. We postulated 
that this might be caused by more variety in dosage of 
carvedilol compared to bisoprolol, although the selec-
tion of type of BB was based on the physician’s prefer-
ence. However, initial treatment dose equivalent, 1-year 
maintenance rates, and doses were similar between the 
carvedilol and bisoprolol groups. This would support 
that both carvedilol and bisoprolol are well-tolerated in 
hospitalized patients with AHF and HFrEF after stabili-
zation. 
Konishi et al. [23] found that 107 patients with se-
vere congestive HF on bisoprolol and 110 patients on 
carvedilol had similar clinical outcomes. However, the 
group also found that bisoprolol had greater benefits in 
patients with HF and concurrent atrial fibrillation than 
did similar patients taking carvedilol. In contrast to 
the previous study, we did not identify any significant 
interactions between BB type and various patient sub-
groups, including those with atrial fibrillation. In the 
future, a large randomized controlled trial is needed to 
substantiate our findings and identify any differences 
between carvedilol and bisoprolol in this specific popu-
lation.
With regard to AHF, many physicians are concerned 
with the initiation or maintenance of BBs given their 
negative inotropic properties, which can exacerbate or-
gan hypoperfusion and fluid congestion. However, in 
prior studies, use of BB during hospitalization for HF 
was actually associated with a significant reduction in 
the rate of death or re-hospitalization due to HF [24-26]. 
Furthermore, the IMPACT-HF trial found that pre-dis-
charge use of carvedilol improved the use of BB at 60 
days without an increase in side effects or length of stay 
in hospitalized patients with acute decompensated HF 
[27]. The OPTIMIZE-HF trial also showed that treat-
ment with carvedilol or another evidence-based BB 
at discharge was well-tolerated and reduced mortality 
risk compared to that in patients who were not pre-
scribed a BB on discharge [20]. In this study, we found 
a similar mortality benefit with BB use upon discharge 
of patients hospitalized for AHF. In addition, our data 
showed that there was no significant difference in the 
all-cause mortality benefit between treatment with 
carvedilol and bisoprolol in patients with AHF. These 
results suggest that a BB ought to be initiated after sta-
bilization of AHF during hospitalization, as stated in 
the current guidelines [1,2]. Furthermore, our findings 
suggest that the type of BB, at least between carvedilol 
or bisoprolol, does not affect the mortality benefit.
This study has several limitations. First, the KorAHF 
registry was not a randomized controlled trial. There-
fore, the specific types of BBs used may have reflected 
individual physician preferences. We also did not have 
information regarding the reasons why physicians did 
not prescribe a BB to some patients at discharge af-
ter stabilization of their AHF. A future well-designed 
randomized controlled trial for comparing carvedilol 
and bisoprolol would be helpful to confirm our study. 
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A second limitation is that, although we performed 
risk adjustments for potential confounding factors, in-
cluding propensity score matching, we were unable to 
adjust for unmeasured variables. Third, because most 
participating centers in this study were large tertiary 
hospitals in Korea, patients with de novo HF were more 
frequently included compared to the other HF registry 
data. In this regard, relatively low rates of mortality 
may be observed, and our results cannot be extrapolat-
ed to patients admitted to primary care hospitals with 
small volume. Finally, this study was not adequately 
powered to assess outcome differences among other ev-
idence-based BBs, including metoprolol and nebivolol, 
because of their low prescription rate.
In the treatment of AHF with reduced EF after hospi-
talization, patients prescribed a BB upon discharge had 
significantly lower risk of all-cause mortality compared 
to those who were not prescribed a BB. The mortality 
benefits of carvedilol and bisoprolol were comparable 
in AHF patients with HFrEF.
Conflict of interest
No potential conflict of interest relevant to this article 
was reported.
Acknowledgments
This work was supported by the Research of Korea Cen-
ters for Disease Control and Prevention (2010-E63003-00, 
2011-E63002- 00, 2012-E63005-00, 2013-E63003-00, 2013-
18 E63003-01, 2013- E63003-02, and 2016-ER6303-00). 
REFERENCES
1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guide-
lines for the diagnosis and treatment of acute and chron-
ic heart failure: the task force for the diagnosis and treat-
ment of acute and chronic heart failure of the European 
Society of Cardiology (ESC) Developed with the special 
contribution of the Heart Failure Association (HFA) of 
the ESC. Eur Heart J 2016;37:2129-2200.
2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA 
guideline for the management of heart failure: a report of 
the American College of Cardiology Foundation/Ameri-
can Heart Association Task Force on Practice Guidelines. 
J Am Coll Cardiol 2013;62:e147-e239.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in 
chronic heart failure: Metoprolol CR/XL Randomised In-
tervention Trial in Congestive Heart Failure (MERIT-HF). 
Lancet 1999;353:2001-2007.
4. CIBIS-II Investigators and Committees. The Cardiac In-
sufficiency Bisoprolol Study II (CIBIS-II): a randomised 
trial. Lancet 1999;353:9-13.
5. Packer M, Bristow MR, Cohn JN, et al. The effect of carve-
dilol on morbidity and mortality in patients with chronic 
heart failure. U.S. Carvedilol Heart Failure Study Group. 
N Engl J Med 1996;334:1349-1355.
6. Packer M, Fowler MB, Roecker EB, et al. Effect of carve-
dilol on the morbidity of patients with severe chronic 
heart failure: results of the carvedilol prospective ran-
domized cumulative survival (COPERNICUS) study. Cir-
culation 2002;106:2194-2199.
7. Gilbert EM, Abraham WT, Olsen S, et al. Comparative 
hemodynamic, left ventricular functional, and antiadren-
ergic effects of chronic treatment with metoprolol versus 
carvedilol in the failing heart. Circulation 1996;94:2817-
2825.
8. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Compar-
ison of carvedilol and metoprolol on clinical outcomes 
in patients with chronic heart failure in the Carvedilol Or 
Metoprolol European Trial (COMET): randomised con-
trolled trial. Lancet 2003;362:7-13.
9. Pasternak B, Svanstrom H, Melbye M, Hviid A. Associa-
tion of treatment with carvedilol vs metoprolol succinate 
and mortality in patients with heart failure. JAMA Intern 
Med 2014;174:1597-1604.
10. Frohlich H, Torres L, Tager T, et al. Bisoprolol compared 
with carvedilol and metoprolol succinate in the treat-
KEY MESSAGE
1. In the treatment of acute heart failure with re-
duced ejection fraction after hospitalization, use 
of a β-blocker at discharge shows a mortality 
benefit in patients with acute heart failure with 
reduced ejection fraction.
2. The mortality benefits of carvedilol and bisop-
rolol, which are widely used and have demon-
strated supporting evidence for the treatment 
of heart failure, are comparable in acute heart 
failure patients with reduced ejection fraction.
1039
Choi KH, et al. Carvedilol vs. bisoprolol in HFrEF
www.kjim.orghttps://doi.org/10.3904/kjim.2018.009
ment of patients with chronic heart failure. Clin Res Car-
diol 2017;106:711-721.
11. Frohlich H, Zhao J, Tager T, et al. Carvedilol compared 
with metoprolol succinate in the treatment and progno-
sis of patients with stable chronic heart failure: carvedilol 
or metoprolol evaluation study. Circ Heart Fail 2015;8:887-
896.
12. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Kon-
stam MA, Udelson JE. Comparative effects of carvedilol 
and metoprolol on left ventricular ejection fraction 
in heart failure: results of a meta-analysis. Am Heart J 
2001;141:899-907.
13. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits 
of β blockers in patients with heart failure and reduced 
ejection fraction: network meta-analysis. BMJ 2013;346:f55.
14. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and 
outcome of acute heart failure in Korea: results from the 
Korean Acute Heart Failure registry (KorAHF). Korean 
Circ J 2017;47:341-353.
15. Lee SE, Cho HJ, Lee HY, et al. A multicentre cohort study 
of acute heart failure syndromes in Korea: rationale, de-
sign, and interim observations of the Korean Acute Heart 
Failure (KorAHF) registry. Eur J Heart Fail 2014;16:700-
708.
16. Schiller NB, Shah PM, Crawford M, et al. Recommenda-
tions for quantitation of the left ventricle by two-dimen-
sional echocardiography. American Society of Echocar-
diography Committee on Standards, Subcommittee on 
Quantitation of Two-Dimensional Echocardiograms. J 
Am Soc Echocardiogr 1989;2:358-367.
17. Levey AS, Coresh J, Greene T, et al. Using standardized 
serum creatinine values in the modification of diet in 
renal disease study equation for estimating glomerular 
filtration rate. Ann Intern Med 2006;145:247-254.
18. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carve-
dilol improves left ventricular function and reduces 
cardiovascular hospitalization in Japanese patients with 
chronic heart failure: the Multicenter Carvedilol Heart 
Failure Dose Assessment (MUCHA) trial. Am Heart J 
2004;147:324-330.
19. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term 
effects of carvedilol in idiopathic dilated cardiomyopa-
thy with persistent left ventricular dysfunction despite 
chronic metoprolol. The Heart-Muscle Disease Study 
Group. J Am Coll Cardiol 1999;33:1926-1934.
20. Fonarow GC, Abraham WT, Albert NM, et al. Carvedilol 
use at discharge in patients hospitalized for heart failure 
is associated with improved survival: an analysis from 
Organized Program to Initiate Lifesaving Treatment in 
Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
Am Heart J 2007;153:82.
21. Hori M, Nagai R, Izumi T, Matsuzaki M. Efficacy and 
safety of bisoprolol fumarate compared with carvedilol 
in Japanese patients with chronic heart failure: results 
of the randomized, controlled, double-blind, Multistep 
Administration of bisoprolol IN Chronic Heart Failure II 
(MAIN-CHF II) study. Heart Vessels 2014;29:238-247.
22. Bolling R, Scheller NM, Kober L, Poulsen HE, Gislason 
GH, Torp-Pedersen C. Comparison of the clinical out-
come of different beta-blockers in heart failure patients: 
a retrospective nationwide cohort study. Eur J Heart Fail 
2014;16:678-684.
23. Konishi M, Haraguchi G, Kimura S, et al. Comparative 
effects of carvedilol vs bisoprolol for severe congestive 
heart failure. Circ J 2010;74:1127-1134.
24. Butler J, Young JB, Abraham WT, et al. Beta-blocker use 
and outcomes among hospitalized heart failure patients. 
J Am Coll Cardiol 2006;47:2462-2469.
25. Metra M, Torp-Pedersen C, Cleland JG, et al. Should 
beta-blocker therapy be reduced or withdrawn after an 
episode of decompensated heart failure? Results from 
COMET. Eur J Heart Fail 2007;9:901-909.
26. Fonarow GC, Abraham WT, Albert NM, et al. Influence of 
beta-blocker continuation or withdrawal on outcomes in 
patients hospitalized with heart failure: findings from the 
OPTIMIZE-HF program. J Am Coll Cardiol 2008;52:190-
199.
27. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheo-
rghiade M; IMPACT-HF Investigators and Coordinators. 
Predischarge initiation of carvedilol in patients hospital-
ized for decompensated heart failure: results of the Initi-
ation Management Predischarge: Process for Assessment 
of Carvedilol Therapy in Heart Failure (IMPACT-HF) 
trial. J Am Coll Cardiol 2004;43:1534-1541.
       
www.kjim.org
The Korean Journal of Internal Medicine Vol. 34, No. 5, September 2019
https://doi.org/10.3904/kjim.2018.009
Supplementary Table 1. Baseline clinical, laboratory characteristics, treatment strategy, and outcomes on admission according 
to prescription of β-blocker
Characteristic BB (n = 1,707) No BB (n = 1,309) p value
Age, yr 64.96 ± 14.7 67.34 ± 14.9 < 0.001a
Male sex 1,036 (60.7) 809 (61.8) 0.560
Current smoker 405 (23.7) 248 (18.9) 0.002a
Body mass index, kg/m2 23.5 ± 3.9 22.8 ± 3.8 < 0.001a
Hypertension 958 (56.1) 703 (53.7) 0.199
Diabetes mellitus 644 (37.7) 466 (35.6) 0.245
Chronic kidney disease 214 (12.5) 212 (16.2) 0.005a
Pulmonary disease 137 (8.0) 174 (13.3) < 0.001a
Prior HF admission 483 (28.3) 513 (39.2) < 0.001a
De novo HF 977 (57.2) 576 (44.0) < 0.001a
ICMP 696 (40.8) 551 (42.1) 0.489
Atrial fibrillation 507 (29.7) 367 (28.0) 0.338
NYHA ≥ 3 1,461 (85.6) 1,136 (86.8) 0.375
SBP, mmHg 131.5 ± 29.1 125.2 ± 28.2 < 0.001a
DBP, mmHg 81.9 ± 18.9 76.9 ± 17.6 < 0.001a
Pulse rate, beats/min 95.7 ± 24.6 95.5 ± 25.6 0.809
LVEF, % 26.7 ± 7.4 26.8 ± 7.5 0.758
Sodium, mmol/L 137.9 ± 4.4 137.1 ± 4.9 < 0.001a
Creatinine, mg/dL 1.47 ± 1.4 1.52 ± 1.5 0.333
Hemoglobin, g/dL 12.9 ± 2.3 12.6 ± 2.3 < 0.001a
AAs at discharge 970 (56.8) 610 (46.6) < 0.001a
RASB at discharge 1,408 (82.5) 885 (67.6) < 0.001a
Loop diuretics 1,615 (94.6) 1,232 (94.1) 0.615
Intravenous inotropes 470 (27.5) 562 (42.9) < 0.001a
Transfusion  238 (13.9) 280 (21.4) < 0.001a
Mechanical ventilation 186 (10.9) 215 (16.4) < 0.001a
Renal replacement therapy 99 (5.8) 89 (6.8) 0.294
Assist deviceb 89 (5.2) 83 (6.3) 0.214
ICU admission 786 (46.0) 671 (51.3) 0.005a
Length of stay, day 12.1 ± 13.8 14.8 ± 18.4 < 0.001a
SBP at discharge, mmHg 113.3 ± 16.9 111.9 ± 16.9 0.025a
Values are presented as mean ± SD or number (%).
BB, β-blocker; HF, heart failure; ICMP, ischemic cardiomyopathy; NYHA, New York Heart Association; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; AA, aldosterone antagonist; RASB, renin an-
giotensin system blocker; ICU, intensive care unit. 
aStatistically significance.
bAssist devices included intra-aortic balloon pumps, left ventricular assist devices, extracorporeal membrane oxygenation, and 
cardiac resynchronization therapy. 
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Supplementary Figure 1. Initial and 1-year follow-up β-block-
er dose equivalent according to carvedilol and bisoprolol. 
Orange bars denotes bisoprolol and blue bars denotes carve-
dilol. ap value for comparison between 1-year follow-up dose 
equivalent between bisoprolol and carvedilol.
